BUSINESSWIRE: The results of phase 2 (there are three) trials of a new drug that reduces testosterone to castrate levels and serum free testosterone to levels lower than orchiectomy or LHRH analogs – without bone loss or hot flashes- are about to be reported in the US. READ MORE>
Archive for the ‘Testosterone treatment’ Category
Results soon of phase two trials of new testosterone-lowering drug
Posted in Testosterone treatment, tagged advanced prostate cancer, Bone loss, BUSINESSWIRE, cancer research, castrate level, catheter, comparison of treatments, GTx-758, hot flashes, LHRH analogs, orchiectomy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate treatment, prostate treatment debate on August 15, 2010| Leave a Comment »
Testosterone slow to return after years of hormone therapy for prostate cancer
Posted in Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, tagged advanced prostate cancer, androgen-deprivation therapy, cancer research, catheter, Hormone therapy, long-term androgen deprivation therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, recovery of testosterone, URO TODAY on June 12, 2010| Leave a Comment »
URO TODAY: The recovery of testosterone after long-term androgen deprivation therapy for prostate cancer is slow, according to a study of about 20 patients who had been receiving hormone drugs for a mean seven years. READ MORE>
NEW FIND: Prostate cancer may be caused by high-dose testosterone leaking from testes to prostate
Posted in PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, PSA tests, Testosterone treatment, Treatment news, Uncategorized, tagged androgen-deprivation therapy, cancer research, cause of prostate cancer, decrease in prostate volume, disappearance of cancerous cells, Hormone therapy, interventional radiological procedure, Israel, Maynei Hayeshua medical center, medical scientists in Israel, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, PSA, PSA test, Radiotherapy, Rehovot, repeat biopsies, super-selective intraprostatic androgen deprivation therapy, testicular and prostate venous (blood) drainage systems, testosterone leaks, URO TODAY, very highly concentrated testosterone, Weizmann Institute of Science on October 6, 2009| Leave a Comment »
URO TODAY: It’s very early days, but medical scientists in Israel may have made a new discovery about the cause of prostate cancer and subsequently how to treat it. READ MORE>
They believe that as men age, very highly concentrated testosterone leaks to the prostate gland via the testicular and prostate venous (blood) drainage systems.
They tried treating six men with an “interventional radiological procedure and super-selective intraprostatic androgen deprivation therapy” and in five cases achieved a decrease in prostate size and in PSA levels, with repeat biopsies showing disappearance of cancerous cells.
The work is being done at Maynei Hayeshua medical center and Department of Condensed Matter Physics, Weizmann Institute of Science, Rehovot, Israel.
At NEW PROSTATE CANCER INFOLINK, Mike Scott writes:
This is clearly a radical new finding that needs to be confirmed by other research groups.
Should it prove to be accurate, we may have a whole new mechanism available to treat early stage disease without having to expose patients to systemic forms of hormone therapy.
The “New” Prostate Cancer InfoLink emphasizes, however, that we have seen only an abstract of this report, and we need greater detail to understand what is actually being suggested by Gat and colleagues. READ MORE>
False balls that release bone-loss drugs may make testicle removal viable option again
Posted in Bone loss, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, Treatment news, tagged advanced prostate cancer, androgen-deprivation therapy, Bone loss, cancer research, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, slow-release drugs, testes removal, testicular prostheses, testosterone control, URO TODAY on September 15, 2009| Leave a Comment »
URO TODAY: Testicular prostheses that slow-release drugs to combat bone loss in men being treated for advanced prostate cancer, have the potential to restore testes removal as a viable option for testosterone control. READ MORE>
Low – not high – levels of testosterone may be new culprit in prostate cancer
Posted in Diagnosis, Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, Testosterone treatment, Treatment debate, tagged advanced stage of presentation, androgen-deprivation therapy, cancer research, high Gleason score, high serum testosterone, Hormone therapy, increased risk of biochemical recurrence after surgery, low serum testosterone, new testosterone evidence, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, testosterone, testosterone levels, URO TODAY, worrisome cancer features on September 6, 2009| Leave a Comment »
URO TODAY: High levels of testosterone have until recently been regarded as dangerous for prostate cancer patients, but new evidence is emerging that suggests something different. READ MORE>
Provocative new evidence suggests that it is not high serum testosterone that is problematic for prostate cancer, but low serum testosterone that is associated with worrisome cancer features and outcomes, such as high Gleason score, advanced stage of presentation, and increased risk of biochemical recurrence after surgery.
New testosterone blocker for advanced prostate cancer shown to be effective with no side effects
Posted in Hormone therapy, New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, Treatment news, tagged advanced prostate cancer, allergic reactions, cancer research, Degarelix, gonadotrophin-releasing hormone antagonist/receptor blocker, hormonal treatment, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Swedish research, URO TODAY, well tolerated on August 16, 2009| Leave a Comment »
URO TODAY: Swedish research shows a new treatment for advanced prostate cancer, the gonadotrophin-releasing hormone antagonist/receptor blocker Degarelix, is well tolerated, with no systemic allergic reactions. READ MORE>
This new agent represents an important pharmacological development in the hormonal treatment of prostate cancer.
New drug dutasteride shown to be more effective than older variant (finasteride) in treating prostate cancer
Posted in PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, Treatment news, tagged 5-alpha reductase, advanced prostate cancer, androgen-deprivation therapy, benign prostatic hyperplasia (BPH), cancer research, comparison of treatments, dihydro-testosterone (DHT), dual inhibition, Dutasteride, finasteride, genetic variants of 5-AR, over-abundance of DHT, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, reduction of testosterone, shrink tumour volume, testosterone-reducing enzyme 5-AR, University of British Columbia, URO TODAY on August 9, 2009| Leave a Comment »
URO TODAY: The dual inhibition of both types 1 and 2 of the testosterone-reducing enzyme 5-AR with the new drug dutasteride may prove more useful than another commonly used drug, finasteride, in treating prostate cancer. READ MORE>
A review just published by the Department of Urologic Sciences, University of British Columbia Vancouver says:
Normal growth and function of the prostate are contingent on the reduction of testosterone to dihydro-testosterone (DHT) by 5-alpha reductase (5-AR) enzymes types 1 and 2.
It has been theorised that an over-abundance of DHT may be implicated in the pathogenesis of both benign prostatic hyperplasia (BPH) and prostate cancer.Dutasteride inhibits both types 1 and 2, whereas finasteride inhibits type 2 only.
Available data show that dutasteride, in contrast to finasteride, provides greater suppression of DHT than finasteride, is able to shrink tumour volume quicker and more dramatically than finasteride, and is more effective against genetic variants of 5-AR than is finasteride.
Thus, full clinical investigations of these and other approaches to the inhibition of 5-AR are ongoing and results are greatly anticipated.
NZ docs too ‘scared’ to try some prostate cancer treatments with proven overseas records
Posted in Biochemical recurrence, Bone cancer, Chemotherapy, Hormone therapy, Hormone-refactory, PROSTATE CANCER, Prostate drugs, Prostate stories, PSA tests, Salvage therapy, Survival, Testosterone treatment, Treatment debate, Wives' stories, tagged advanced prostate cancer, comparison of treatments, Hormone therapy, inflexible approaches, Keto, ketoconazole, NZ doctors, NZ medical professionals, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, PSA, PSA test, side effects on July 12, 2009| Leave a Comment »
JULY 10: PROSTABLOG NZ: “It’s sad that medical professionals in NZ are so scared of possible side effects from a treatment like Ketoconazole, that they refuse to even acknowledge it, even if it has been proven to be effective overseas.”
These words were written today by Mary – a Kiwi whose partner has advanced prostate cancer – as she describes the frustration of being unable to persuade NZ doctors to move outside what seem to her to be inflexible approaches to treatment.
“I produced prostate cancer digests from people I know who have had large drops in PSA on Keto, but I was told I know only a few people and trials showing side effects have been done on thousands,” she says.
“When I said I would like to see the papers on this, I was told I was not a doctor…and to this I respond “no, but I am the partner of a man with advanced cancer.”
READ the second chapter of Mary’s struggle to save her man.
